Market Cap | 1.63M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -179.67M | Forward P/E | -0.02 | EPS next Y | - | 50D Avg Chg | -9.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -84.00% |
Dividend | N/A | Price/Book | 0.11 | EPS next 5Y | - | 52W High Chg | -99.00% |
Recommedations | 3.00 | Quick Ratio | 1.87 | Shares Outstanding | 90.48M | 52W Low Chg | 38.00% |
Insider Own | 5.50% | ROA | -46.63% | Shares Float | 85.39M | Beta | 2.21 |
Inst Own | 0.39% | ROE | -185.31% | Shares Shorted/Prior | 1.53M/2.48M | Price | 0.02 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 121,110 | Target Price | - |
Oper. Margin | - | Earnings Date | Feb 26 | Volume | 46,552 | Change | 2.86% |
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.
Guggenheim | Neutral | Sep 13, 22 |
Morgan Stanley | Equal-Weight | Sep 9, 22 |
SVB Leerink | Market Perform | Aug 9, 22 |
Morgan Stanley | Equal-Weight | May 11, 22 |
HC Wainwright & Co. | Buy | May 11, 22 |
SVB Leerink | Market Perform | May 10, 22 |
Morgan Stanley | Equal-Weight | Apr 11, 22 |
Guggenheim | Buy | Apr 11, 22 |
HC Wainwright & Co. | Buy | Apr 11, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Appelhans Dannielle | CEO and President CEO and President | Feb 24 | Sell | 0.1274 | 10,385 | 1,323 | 02/27/23 | |
CAGNONI PABLO J | Director Director | Feb 01 | Sell | 0.25 | 8,448 | 2,112 | 66,082 | 02/01/23 |
Appelhans Dannielle | CEO and President CEO and President | Jan 31 | Sell | 0.25 | 3,878 | 970 | 10,385 | 02/01/23 |
CAGNONI PABLO J | Director Director | Jan 29 | Sell | 0.24 | 7,240 | 1,738 | 74,530 | 01/31/23 |
Turka Laurence A. | Chief Scientific Off.. Chief Scientific Officer | Jan 29 | Sell | 0.24 | 2,593 | 622 | 18,391 | 01/31/23 |
Appelhans Dannielle | Chief Operating Offi.. Chief Operating Officer | Aug 09 | Sell | 0.8 | 5,737 | 4,590 | 6,763 | 08/12/22 |
Epstein David R | Director Director | Apr 21 | Buy | 1.4443 | 30,000 | 43,329 | 4,720,012 | 04/22/22 |
CAGNONI PABLO J | CEO and President CEO and President | Jan 29 | Sell | 6.57 | 6,730 | 44,216 | 35,520 | 02/01/22 |
Keson-Brookes Maiken | CLO & Corp. Secretar.. CLO & Corp. Secretary | Jan 29 | Sell | 6.57 | 2,732 | 17,949 | 5,343 | 02/01/22 |
Turka Laurence A. | Chief Scientific Off.. Chief Scientific Officer | Jan 29 | Sell | 6.57 | 2,517 | 16,537 | 4,921 | 02/01/22 |
Epstein David R | Director Director | Feb 10 | Sell | 14.84 | 98,737 | 1,465,257 | 4,716,716 | 02/10/21 |